The main clinically relevant difference between the two patient cohorts may have been the access to post-chemotherapy maintenance treatment regimens such as antiangiogenetic agents, attributed to the highly significant licensing and funding between EMA and NICE.
← all excerpts
Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
1
—
—